In a review of data from the Nationwide Readmissions Database, researchers found that women with ovarian cancer classified as frail were at higher risk for need of intensive care, nonroutine discharge, and readmissions after surgery.
Broad use of PARP inhibitors to treat advanced-stage ovarian cancer would be associated with high costs compared with their biomarker-directed use.
Researchers identified factors for increased risk of clinically significant fatigue among women who underwent surgery for gynecologic cancers.
Patients with low-grade serous carcinoma of the ovary or peritoneum (LGSC) developed chemoresistance to neoadjuvant platinum-based therapy.
Study results differ from prior research into microRNAs as predictive biomarkers.